Cargando…
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
BACKGROUND AND OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG)–seropositive NMOSD (eculizumab, inebilizumab, and sa...
Autores principales: | Paul, Friedemann, Marignier, Romain, Palace, Jacqueline, Arrambide, Georgina, Asgari, Nasrin, Bennett, Jeffrey L., Cree, Bruce Anthony Campbell, De Sèze, Jérôme, Fujihara, Kazuo, Kim, Ho Jin, Hornby, Rebecca, Huda, Saif, Kissani, Najib, Kleiter, Ingo, Kuwabara, Satoshi, Lana-Peixoto, Marco, Law, Lisa, Leite, M. Isabel, Pandit, Lekha, Pittock, Sean J., Quan, Chao, Ramanathan, Sudarshini, Rotstein, Dalia, Saiz, Albert, Sato, Douglas Kazutoshi, Vaknin-Dembinsky, Adi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231913/ https://www.ncbi.nlm.nih.gov/pubmed/37258412 http://dx.doi.org/10.1212/NXI.0000000000200124 |
Ejemplares similares
-
Sensitivity analysis of the primary endpoint from the N-MOmentum
study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021) -
Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
por: Saab, Georges, et al.
Publicado: (2022) -
Eculizumab monotherapy for NMOSD: Data from PREVENT and its
open-label extension
por: Pittock, Sean J, et al.
Publicado: (2021) -
Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022) -
Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
por: Wingerchuk, Dean M., et al.
Publicado: (2021)